A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future DirectionsEvan S. Dellon, Seema S. Aceves, Alex Straumann et al.|Gastroenterology|2022Cited by 109
Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of AgeMirna Chehade, Jennifer Maloney, Naimish Patel et al.|New England Journal of Medicine|2024Cited by 107
Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS)Christopher Ma, Philip E. Putnam, Ikuo Hirano et al.|Journal of Allergy and Clinical Immunology|2021Cited by 82
Dupilumab Improves Histologic And Endoscopic Outcomes In Children Aged 1 To <12 Years With Eosinophilic Esophagitis (EoE): 52-Week Results From The Phase 3 EoE KIDS TrialMirna Chehade, Arsalan Shabbir, Evan S. Dellon et al.|Journal of Allergy and Clinical Immunology|2024Cited by 7